| Daniel Safranek, MD | |
|
3200 Providence Dr, Anchorage, AK 99508-4661 | |
| (907) 261-3111 | |
| (907) 565-8066 |
| Full Name | Daniel Safranek |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 27 Years |
| Location | 3200 Providence Dr, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417944687 | NPI | - | NPPES |
| MD22301 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | 4013 (Alaska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Alaska Medical Center | Anchorage, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alaska Emergency Medicine Associates | 5193639912 | 22 |
News Archive
There is a lesson in this unexpected juxtaposition nevertheless: No nation can safely base its tax and spending plans on inflexible commitments. Political life, both domestic and international, is too unpredictable. Yet U.S. government spending is mostly on autopilot. The government is scheduled to lay out $3.8 trillion this fiscal year -; 70 percent of which will go to mandatory-spending programs, chiefly Social Security, Medicare, Medicaid and interest on the federal debt. Mr. Obama's plan for fiscal 2015 does not change this; it would increase overall spending slightly, paying for it with selected tax increases, while shifting money among priorities here and there. But these tweaks would take place within the same 30 percent of discretionary spending that the current budget contains (3/4).
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.
Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.
A team of US-based scientists has recently conducted a survey to determine the willingness of healthcare workers towards coronavirus disease 2019 (COVID-19) vaccinations.
› Verified 7 days ago
| Entity Name | Alaska Emergency Medicine Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568450476 PECOS PAC ID: 5193639912 Enrollment ID: O20031117000406 |
News Archive
There is a lesson in this unexpected juxtaposition nevertheless: No nation can safely base its tax and spending plans on inflexible commitments. Political life, both domestic and international, is too unpredictable. Yet U.S. government spending is mostly on autopilot. The government is scheduled to lay out $3.8 trillion this fiscal year -; 70 percent of which will go to mandatory-spending programs, chiefly Social Security, Medicare, Medicaid and interest on the federal debt. Mr. Obama's plan for fiscal 2015 does not change this; it would increase overall spending slightly, paying for it with selected tax increases, while shifting money among priorities here and there. But these tweaks would take place within the same 30 percent of discretionary spending that the current budget contains (3/4).
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.
Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.
A team of US-based scientists has recently conducted a survey to determine the willingness of healthcare workers towards coronavirus disease 2019 (COVID-19) vaccinations.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Safranek, MD 3427 E Tudor Rd, Ste A, Anchorage, AK 99507-1282 Ph: (907) 565-8005 | Daniel Safranek, MD 3200 Providence Dr, Anchorage, AK 99508-4661 Ph: (907) 261-3111 |
News Archive
There is a lesson in this unexpected juxtaposition nevertheless: No nation can safely base its tax and spending plans on inflexible commitments. Political life, both domestic and international, is too unpredictable. Yet U.S. government spending is mostly on autopilot. The government is scheduled to lay out $3.8 trillion this fiscal year -; 70 percent of which will go to mandatory-spending programs, chiefly Social Security, Medicare, Medicaid and interest on the federal debt. Mr. Obama's plan for fiscal 2015 does not change this; it would increase overall spending slightly, paying for it with selected tax increases, while shifting money among priorities here and there. But these tweaks would take place within the same 30 percent of discretionary spending that the current budget contains (3/4).
Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported positive, statistically significant top-line results from the MARINE study, its first Phase 3 clinical trial of lead drug candidate AMR101.
Pfizer Inc. announced today that top-line results for Lyrica Study A0081107 - Central Neuropathic Pain Following Spinal Cord Injury - demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica compared to placebo.
A team of US-based scientists has recently conducted a survey to determine the willingness of healthcare workers towards coronavirus disease 2019 (COVID-19) vaccinations.
› Verified 7 days ago
John E Hall, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3200 Providence Dr, Anchorage, AK 99508 Phone: 907-261-3111 Fax: 907-565-8066 | |
Sandra Lee Gailey, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-729-1729 Fax: 907-729-1759 | |
Dr. Richard Wood, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 673 Mdg / Jb Elmendorf-richardson Usaf, 5955 Zeamer Ave, Anchorage, AK 99506 Phone: 907-580-5556 | |
William D Longhurst, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-553-2662 | |
Dr. Leigh Martinez Wright, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4315 Diplomacy Dr, Alaska Native Medical Center, Anchorage, AK 99508 Phone: 907-729-1729 | |
Dr. Frank H Moore, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Providence Dr, Anchorage, AK 99508 Phone: 907-261-3111 Fax: 907-565-8066 | |
Tanya M Leinicke, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3200 Providence Dr, Anchorage, AK 99508 Phone: 907-565-8005 Fax: 907-565-8066 |